Roy Herbst shared the updated results from the COAST clinical trial – Yale Cancer Center

Yale Cancer Center shared a post on X:

“Roy Herbst shared the updated results from the COAST clinical trial, a phase 2 study of durvalumab with/without oleclumab or monalizumab in patients with stage 3 unresectable NSCLC.”